Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA03 - Biomarkers for Immunotherapy: Are All Relevant?

    • 10:45 - 11:45
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • +

      MA03.01 - EPICAL Trial. A Phase Ib StudyCombining Anti-Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR-Mutant Non-Small Cell Lung Cancer

      10:45 - 10:50  |  Presenter: Silvia Garcia-Roman

      • Abstract

      Loading...

    • +

      MA03.02 - TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors

      10:50 - 10:55  |  Presenter: Edward B Garon

      • Abstract

      Loading...

    • +

      MA03.03 - NBTXR3 Activated by SBRT Combined with Nivolumab or Pembrolizumab in Patients With Advanced Cancers: Phase I Trial

      10:55 - 11:00  |  Presenter: Colette Shen

      • Abstract

      Loading...

    • +

      MA03.04 - Discussant

      11:00 - 11:15  |  Presenter: Giannis Mountzios

      • Abstract

      No abstract available for this presentation

    • +

      MA03.05 - DNA Damage Response (DDR) Gene Mutations and Correlation With Immunotherapy Response in NSCLC Patients

      11:15 - 11:20  |  Presenter: Jiaqing Liu

      • Abstract

      Loading...

    • +

      MA03.06 - ctDNA Mass-Adjusted bTMB as a Predictive Biomarker in NSCLC Patients Receiving PD-(L)1 Inhibitors

      11:20 - 11:25  |  Presenter: Wei Nie

      • Abstract

      Loading...

    • +

      MA03.07 - Interferon-Gamma Mediated Immune Evasion: A Potential Mechanism of Resistance to Immunotherapy in Non-Small Cell Lung Cancer

      11:25 - 11:30  |  Presenter: Fasheng Li

      • Abstract

      Loading...

    • +

      MA03.08 - Discussant

      11:30 - 11:45  |  Presenter: Solange Peters

      • Abstract

      No abstract available for this presentation

  • +

    MA04 - Current Status and Future Prospects of Pleural Mesothelioma and Thymoma

    • 10:45 - 11:45
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
    • +

      MA04.01 - Multimodality Treatment and Outcome in Stage III Thymic Epithelial Tumors (TETs): A Retrospective Analysis From the French RYTHMIC Network

      10:45 - 10:50  |  Presenter: Jose Carlos Benítez

      • Abstract

      Loading...

    • +

      MA04.02 - Characteristics of Genomic Alterations in Chinese Patients with Thymic Epithelial Tumors

      10:50 - 10:55  |  Presenter: Xinglong Fan

      • Abstract

      Loading...

    • +

      MA04.03 - A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor (KCSG LU17-21)

      10:55 - 11:00  |  Presenter: Hyun Ae Jung

      • Abstract

      Loading...

    • +

      MA04.04 - Discussant

      11:00 - 11:15  |  Presenter: Paul Baas

      • Abstract

      No abstract available for this presentation

    • +

      MA04.05 - Survival Benefit of Multiagent Chemotherapy With and Without Curative Surgery for Malignant Pleural Mesothelioma

      11:15 - 11:20  |  Presenter: Ahmed Alnajar

      • Abstract

      Loading...

    • +

      MA04.06 - MicroRNAs Contribute to the Chemotherapy Response of Malignant Pleural Mesothelioma

      11:20 - 11:25  |  Presenter: Michaela B Kirschner

      • Abstract

      Loading...

    • +

      MA04.07 - Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection

      11:25 - 11:30  |  Presenter: Susana Cedres

      • Abstract

      Loading...

    • +

      MA04.08 - Discussant

      11:30 - 11:45  |  Presenter: Francoise Galateau-Salle

      • Abstract

      No abstract available for this presentation

  • +

    OA05 - Palliative Care Service Models

    • 10:45 - 11:45
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Palliative and Supportive Care
    • +

      OA05.01 - Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With an Advanced Thoracic Malignancy

      10:45 - 10:55  |  Presenter: Kelly C. Gast

      • Abstract

      Loading...

    • +

      OA05.02 - Acceptability of Automatic Referrals to Supportive and Palliative Care, by Patients Living with Advanced Lung Cancer: A Co-Design Process

      10:55 - 11:05  |  Presenter: Desiree Hao

      • Abstract

      Loading...

    • +

      OA05.03 - Onco-Pall Clinic: An Embedded Care Model for Thoracic Malignancy

      11:05 - 11:15  |  Presenter: Julia Lynn Agne

      • Abstract

      Loading...

    • +

      OA05.04 - Discussant

      11:15 - 11:25  |  Presenter: Brian Le

      • Abstract

      No abstract available for this presentation

    • +

      OA05.05 - Live Discussion with Speakers

      11:25 - 11:45

      • Abstract

      No abstract available for this presentation

  • +

    IS01 - Industry Symposium Sponsored by Mirati Therapeutics: Rapid Progress During a Pandemic: Emerging Therapeutic Options for NSCLC

    • 12:00 - 13:00
    • 9/08/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS01.01 - Welcome and Introduction

      12:00 - 12:05  |  Presenter: Pasi A. Janne

      • Abstract

      No abstract available for this presentation

    • +

      IS01.02 - Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC

      12:05 - 12:20  |  Presenter: Suresh Ramalingam

      • Abstract

      No abstract available for this presentation

    • +

      IS01.03 - Targeting Checkpoint Inhibitor Resistance in NSCLC

      12:20 - 12:35  |  Presenter: Solange Peters

      • Abstract

      No abstract available for this presentation

    • +

      IS01.04 - Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-Driven NSCLC

      12:35 - 12:50  |  Presenter: Pasi A. Janne

      • Abstract

      No abstract available for this presentation

    • +

      IS01.05 - Live Q&A

      12:50 - 13:00

      • Abstract

      No abstract available for this presentation

  • +

    IS02 - Satellite CME Symposium by Med Learning Group: A New Era of Treatment Opportunities for Small-Cell Lung Cancer in the Second Line: An Innovative 3D View

    • 12:00 - 13:00
    • 9/08/2021
    • Location: Program Auditorium
    • CME Accredited by Other Provider
    • Type: Satellite CME Symposia
    • Track: N.A.
    • +

      IS02.01 - Response to Primary Therapy and Tumorigenesis of Small Cell Lung Cancer: Subsequent Lines of Therapy and Pathophysiology Primer

      12:00 - 12:15

      • Abstract

      No abstract available for this presentation

    • +

      IS02.02 - Efficacy and Safety Review: Second-Line Regimens for Extensive Stage SCLC

      12:15 - 12:30

      • Abstract

      No abstract available for this presentation

    • +

      IS02.03 - Applying National Cancer Center Network (NCCN) Guidelines to Practice

      12:30 - 12:45

      • Abstract

      No abstract available for this presentation

    • +

      IS02.04 - Conclusions

      12:45 - 12:50

      • Abstract

      No abstract available for this presentation

    • +

      IS02.05 - Live Q&A

      12:50 - 13:00

      • Abstract

      No abstract available for this presentation

  • +

    IS03 - Satellite CME Symposium by RMEI Medical Education: Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

    • 12:00 - 13:00
    • 9/08/2021
    • Location: Program Auditorium
    • CME Accredited by Other Provider
    • Type: Satellite CME Symposia
    • Track: N.A.
    • +

      IS03.01 - Welcome and Introductions

      12:00 - 12:05  |  Presenter: Tony Mok

      • Abstract

      No abstract available for this presentation

    • +

      IS03.02 - EGFR Insertion Mutations in NSCLC: Why and How Do We Test?

      12:05 - 12:20  |  Presenter: Shirish M. Gadgeel

      • Abstract

      No abstract available for this presentation

    • +

      IS03.03 - New and Emerging Therapies with EXON20 INS Mutations

      12:20 - 12:40  |  Presenter: Tony Mok

      • Abstract

      No abstract available for this presentation

    • +

      IS03.04 - Managing Toxicity with Anti-EGFR Exon 20 Agents

      12:40 - 12:50  |  Presenter: Antonio Passaro

      • Abstract

      No abstract available for this presentation

    • +

      IS03.05 - Audience Q&A and Closing Remarks

      12:50 - 13:00

      • Abstract

      No abstract available for this presentation

  • +

    FP01 - Early Stage/Localized Disease/Ablative Therapies

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Early Stage/Localized Disease/Ablative Therapies
    • +

      FP01.01 - The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIA NSCLC

      00:00 - 00:00  |  Presenter: John Varlotto

      • Abstract

      Loading...

    • +

      FP01.02 - A Comparative Cost Analysis Study of Robotic and Video-Assisted Lobectomy: Results of Randomized Controlled Trial (Bravo Trial)

      00:00 - 00:00  |  Presenter: Ricardo Mingarini Terra

      • Abstract

      Loading...

    • +

      FP01.03 - Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC

      00:00 - 00:00  |  Presenter: Sabine Schmid

      • Abstract

      Loading...

    • +

      FP01.04 - Prospective Observational Study of Activities of Daily Livings in Elderly Patients After Lung Cancer Surgery (JCOG1710A)

      00:00 - 00:00  |  Presenter: Hidefumi Takei

      • Abstract

      Loading...

  • +

    FP02 - Health Services Research/Health Economics

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Health Services Research/Health Economics
    • +

      FP02.01 - Utilization and Refusal of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: A National Cancer Database Study

      00:00 - 00:00  |  Presenter: Ranjan Pathak

      • Abstract

      Loading...

    • +

      FP02.02 - The Impact of Sex on Non-Small Cell Lung Cancer Survival in Canada

      00:00 - 00:00  |  Presenter: Chelsea Ann Ford-Sahibzada

      • Abstract

      Loading...

    • +

      FP02.03 - Factors Associated With Delayed Lung Cancer Diagnosis

      00:00 - 00:00  |  Presenter: Andrew Ciupek

      • Abstract

      Loading...

    • +

      FP02.04 - Immunotherapy in Lung Cancer: Analysis of Patients’ Awareness and Perceptions

      00:00 - 00:00  |  Presenter: Christie Lagogianni

      • Abstract

      Loading...

  • +

    FP03 - Immuno-Biology and Novel Immunotherapeutics (Phase I and Translational)

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • +

      FP03.02 - A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients with Metastatic Non-Small Cell Lung Cancer 

      00:00 - 00:00  |  Presenter: Jyoti Malhotra

      • Abstract

      Loading...

    • +

      FP03.03 - ECOG PS of 0-1 and Very High PD-L1 Expression ≥90% Are Associated With Clinical Benefit From First-Line Chemo-Immunotherapy in Advanced NSCLC

      00:00 - 00:00  |  Presenter: Biagio Ricciuti

      • Abstract

      Loading...

    • +

      FP03.04 - Dasatinib Improves the Antitumor Activity of Anti-PD-1 in NSCLC Models by Inhibiting Treg Conversion and Proliferation

      00:00 - 00:00  |  Presenter: Esther Redin

      • Abstract

      Loading...

  • +

    FP04 - Immunotherapy (Phase II/III Trials)

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      FP04.01 - Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907

      00:00 - 00:00  |  Presenter: Natasha Leighl

      • Abstract

      Loading...

    • +

      FP04.02 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

      00:00 - 00:00  |  Presenter: Jie Wang

      • Abstract

      Loading...

    • +

      FP04.03 - Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

      00:00 - 23:59  |  Presenter: Igor Bondarenko

      • Abstract

      Loading...

    • +

      FP04.04 - A Phase Ib/II Study of Imprime PGG and Pembrolizumab in Pretreated Patients With Advanced Stage Non-Small Cell Lung Cancer: BTCRC-LUN15-017

      00:00 - 00:00  |  Presenter: Muhammad Furqan

      • Abstract

      Loading...